The National Cannabis Prevention
and Information Centre (NCPIC)
within the National Drug and
Alcohol Research Centre at the
University of New South Wales led
a study looking at the effects of
Sativex (nabiximols) on cannabis
withdrawal symptoms.
Published in JAMA Psychiatry,
the study found that nabiximols
treatment “significantly reduced
the overall severity of cannabis
withdrawal relative to placebo.”
This included effects on irritability,
depression and cannabis cravings.
The study found that patients
remained in treatment longer
during medication use but that
placebos were as effective as
the drug in promoting long-term
reductions in cannabis use once
medication ceased.
Sativex was administered as an
oral spray, licensed in Australia
for treatment of MS patients and
contained cannabis extracts, the
University said.
To read the report CLICK HERE.The above article was sent to subscribers in Pharmacy Daily's issue from 17 Jan 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Jan 14
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.